Top Markets
Coin of the day
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Rang in Aktien #32453
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Aktienkurs
$1.11
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$10.06M
Veränderung (1 Tag)
1.38%
Veränderung (1 Jahr)
-55.98%
Land
US
Handel Lisata Therapeutics, Inc. (LSTA)

Kategorie

Aktien-Split-Historie für Lisata Therapeutics, Inc. (LSTA)
Die Aktie Lisata Therapeutics, Inc. (Symbol: LSTA) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 18, 2026 statt.
Eine LSTA-Aktie, die vor dem Aug 18, 2026 gekauft wurde, entspricht heute 0 LSTA-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
CH
0 -
KR